FDA approves Novartis kidney disease drug

FDA, Pfizer

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.

MarketWatch on MSN · 9h

Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment

Business Insider · 12h

FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents

Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine

Reuters · 12d

US FDA approves GE HealthCare's diagnostic drug for heart disease

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday.

UPI News on MSN · 19h

FDA approves first once-weekly drug treatment regimen for hemophilia

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.

Bloomberg on MSN · 21h

Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia

Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.

Daily Journal · 21h

FDA Approves New Treatment for Hemophilia A or B

"Today's approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process," said Ann Farrell, M.

Seeking Alpha on MSN · 21h

Pfizer gets FDA approval for Hympavzi for hemophilia

Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX

pharmaphorum4d

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second ... are at risk of rapid disease progression, making it the first complement inhibitor for the rare kidney disease.

Newsweek15d

FDA Approves New Schizophrenia Drug in 70-Year First

The U.S. Food and Drug Administration has approved a new drug for ... causes of disability worldwide, the FDA reports. Individuals with this disease have a greater risk of dying young, and ...

STAT24d

FDA awards Novartis expanded approval for breast cancer therapy

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration ...

Yahoo Finance25d

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...

Medical Xpress24d

FDA expands use of breast cancer drug Kisqali

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the ...

Time15d

FDA Approves the First New Schizophrenia Drug in Decades

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the ...

Investor's Business Daily on MSN2d

Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease

Travere Therapeutics stock popped to a 15-month high Wednesday after a group of experts suggested an alternative means of measuring the success of treatments for a kidney disease.Please watch the ...

Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug

Biogen said it won Food and Drug Administration breakthrough-therapy designation for its proposed treatment for a major cause of kidney-transplant failure.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending on Bing